---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-063981"
form_type: "8-K"
ticker: "BMRN"
cik: "0001048477"
company_name: "BIOMARIN PHARMACEUTICAL INC"
filed_at: "2026-09-30T20:15:40+00:00"
generated_at: "2026-10-12T14:05:45.275749+00:00"
event_type: "litigation"
sentiment: "positive"
materiality_score: 0.68
calibrated_materiality_score: 0.68
confidence: "high"
source: SEC EDGAR
---

# BioMarin settles patent suit with Ascendis; wins 20% US royalty on TransCon CNP through May 2030

## Summary
- BioMarin grants Ascendis a non-exclusive, worldwide, transferable, royalty-bearing license to BioMarin Patent Rights covering navepegritide (TransCon CNP)/Yuviwel, effective August 28, 2026.
- Royalty is 20% of annual US net sales and 18% of net sales in the EU, Brazil and South Korea, running from first commercial sale in each territory until May 2030.
- All pending litigation between the parties over the BioMarin Patent Rights will be dismissed with prejudice; BioMarin releases pre-effective-date infringement claims and covenants not to sue Ascendis.
- Ascendis covenants not to challenge BioMarin's Patent Rights, plus a mutual regulatory non-interference clause; licensed products cover achondroplasia and hypochondroplasia, alone or in combination.

## SEC filing metadata
- accession: 0001628280-26-063981
- form_type: 8-K
- ticker: BMRN
- cik: 0001048477
- company_name: BIOMARIN PHARMACEUTICAL INC
- filed_at: 2026-09-30T20:15:40+00:00
- event_type: litigation
- sentiment: positive
- materiality_score: 0.68
- calibrated_materiality_score: 0.68
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1048477/000162828026063981/0001628280-26-063981-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1048477/000162828026063981/bmrn-20260924.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-063981
- JSON: https://secwatch.observer/filing/0001628280-26-063981.json
- Plain text: https://secwatch.observer/filing/0001628280-26-063981.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.